Abstract:Summary Background Hepatocellular carcinoma (HCC) is a highly prevalent and deadly type of cancer, and although pharmacotherapy remains the cornerstone of treatment, therapeutic outcomes are often unsatisfactory. Pharmacological inhibition of mammalian target of rapamycin (mTOR) has been closely associated with HCC regression. Methods Herein, we covalently conjugated AZD8055, a potent mTORC1/2 blocker, with a small panel of unsaturated fatty acids via a dynamically activating linkage to enable aqueous self-assembly of prodrug conjugates to form mTOR nanoblockers. Cell-based experiments were carried out to evaluate the effects of the nanoblocker against hepatocellular carcinoma (HCC) cells. The orthotopic and subcutaneous HCC mouse models were established to examine its antitumour activity. Findings Among several fatty acids as promoieties, linoleic acid-conjugated self-assembling nanoblocker exhibited optimal size distribution and superior physiochemical properties. Compared with free agents, PEGylated AZD8055 nanoblocker (termed AZD NB) was pharmacokinetically optimized after intravenous administration. In vivo investigations confirmed that AZD NB significantly suppressed tumour outgrowth in subcutaneous HCCLM3 xenograft, Hepatoma-22, and orthotopic Hepa1-6 liver tumour models. Strikingly, treatment with AZD NB, but not free agent, increased intratumour infiltration of IFN-γ + CD8 + T cells and CD8 + memory T cells, suggesting a potential role of the mTOR nanoblocker to remodel the tumour microenvironment. Overall, a single conjugation with fatty acid transformed a hydrophobic mTOR blocker into a systemically injectable nanomedicine, representing a facile and generalizable strategy for improving the therapeutic index of mTOR inhibition-based cancer therapy. Interpretation The mTOR inhibition by chemically engineered nanoblocker presented here had enhanced efficacy against tumours compared with the pristine drug and thus has the potential to improve the survival outcomes of patients with HCC. Additionally, this new nanosystem derived from co-assembling of small-molecule prodrug entities can serve as a delivery platform for the synergistic co-administration of distinct pharmaceutical agents. Funding This work was supported by the National Natural Science Foundation of China ( 32171368 , 81721091 ), the Zhejiang Provincial Natural Science Foundation of China ( LZ21H180001 ), the Jinan Provincial Laboratory Research Project of Microecological Biomedicine ( JNL-2022039c and JNL-2022010B ), State Key Laboratory for Diagnosis and Treatment of Infectious Diseases ( zz202310 ), and Natural Science Foundation of Shandong Province ( ZR2023ZD59 ).

Dual Targeting Of Mtorc1/C2 Complexes Enhances Histone Deacetylase Inhibitor-Mediated Antitumor Efficacy In Primary Hcc Cancer In Vitro And In Vivo

Abstract 5363: Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated antitumor efficacy in primary HCC cancerin vitroandin vivo

BET Protein Inhibition Evidently Enhances Sensitivity to PI3K/mTOR Dual Inhibition in Intrahepatic Cholangiocarcinoma

Combined Targeting of AKT and Mtor Synergistically Inhibits Proliferation of Hepatocellular Carcinoma Cells.

Data from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Combined Targeting of AKT and Mtor Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model.

Vertical Targeting of AKT and Mtor As Well As Dual Targeting of AKT and MEK Signaling is Synergistic in Hepatocellular Carcinoma

Novel Synergistic Antitumor Effects of Rapamycin with Bortezomib on Hepatocellular Carcinoma Cells and Orthotopic Tumor Model

Dual Inhibiting Oct4 and Akt Potently Suppresses the Propagation of Human Cancer Cells

Rational Combination of SHP2 and Mtor Inhibition for the Treatment of Hepatocellular Carcinoma

Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma.

The Anti-Hepatocellular Carcinoma Cell Activity by a Novel Mtor Kinase Inhibitor CZ415

Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma

Pharmacological or Transcriptional Inhibition of Both HDAC1 and 2 Leads to Cell Cycle Blockage and Apoptosis Via P21waf1/cip1 and P19ink4d Upregulation in Hepatocellular Carcinoma.

Inhibition of Mtorc1 Signaling Sensitizes Hepatocellular Carcinoma Cells to Glycolytic Stress

Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy

Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors As a Promising Strategy for Cancer Therapy.

Combination of Cetuximab and Rapamycin Enhances the Therapeutic Efficacy in Hepatocellular Carcinoma.

Combined Inhibition of AURKA and HSF1 Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma by Activating Endoplasmic Reticulum Stress

Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma